Galina Selivanova
- Molecular Biology top 1%
- Oncology top 0.5%
- Cancer Research top 1%
- Biotechnology top 0.2%
- Immunology top 5%
- Co-authors
- Klas G. WimanNatalia IssaevaVladimir J.N. BykovJan BergmanMartin EngeLászló SzékelyMonica HultcrantzMarina Protopopova
- Topics
- Cancer-related Molecular Pathways (67 papers)Cancer Research and Treatments (26 papers)RNA modifications and cancer (21 papers)
- Cited by
- OncologyBiotechnologyCancer Research
- Partner nations
- SwedenRussiaUnited States
In The Last Decade
Galina Selivanova
93 papers receiving 7.2k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Molecular Biology 5.2k
- Oncology 4.5k
- Cancer Research 1.2k
- Biotechnology 1.1k
- Immunology 552
Countries citing papers authored by Galina Selivanova
This map shows the geographic impact of Galina Selivanova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galina Selivanova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galina Selivanova more than expected).
Fields of papers citing papers by Galina Selivanova
This network shows the impact of papers produced by Galina Selivanova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galina Selivanova. The network helps show where Galina Selivanova may publish in the future.
Co-authorship network of co-authors of Galina Selivanova
This figure shows the co-authorship network connecting the top 25 collaborators of Galina Selivanova. A scholar is included among the top collaborators of Galina Selivanova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galina Selivanova. Galina Selivanova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 17 | |
| 2 | 4 | |
| 3 | 113 | |
| 4 | 14 | |
| 5 | 18 | |
| 6 | 53 | |
| 7 | 8 | |
| 8 | 13 | |
| 9 | 28 | |
| 10 | 187 | |
| 11 | 112 | |
| 12 | GeneXplain — Identification of Causal Biomarkers and Drug Targets in Personalized Cancer Pathways | 9 |
| 13 | 67 | |
| 14 | 68 | |
| 15 | 41 | |
| 16 | 93 | |
| 17 | 131 | |
| 18 | 20 | |
| 19 | 47 | |
| 20 | 95 |
About Galina Selivanova
Galina Selivanova is a scholar working on Biotechnology, Oncology and Molecular Biology, having authored 93 papers that have together received 7.3k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (67 papers), Cancer Research and Treatments (26 papers) and RNA modifications and cancer (21 papers). The work is most often cited by research in Oncology (4.5k citations), Biotechnology (1.1k citations) and Cancer Research (1.2k citations). Galina Selivanova has collaborated with scholars based in Sweden, Russia and United States. Frequent co-authors include Klas G. Wiman, Natalia Issaeva, Vladimir J.N. Bykov, Jan Bergman, Martin Enge, László Székely, Monica Hultcrantz, Marina Protopopova, Joanna Zawacka‐Pankau and Przemyslaw Bozko. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.